Details for Patent: 6,916,485

Title:	Prolonged release bioadhesive therapeutic systems
Abstract:	The present invention concerns a prolonged release bioadhesive mucosal therapeutic system containing at least one active principle, with an active dissolution test of more than 70% over 8 hours and to a method for its preparation. The bioadhesive therapeutic system may be in tablet form and may contain quantities of natural proteins representing at least 50% by weight of active principle and at least 20% by weight of the tablet, between 10% and 20% of a hydrophilic polymer, and compression excipients, and may contain between 4% and 10% of an alkali metal alkylsulphate to reinforce the local availability of active principle and between 0.1% and 1% of a monohydrate sugar.
Inventor(s):	Aiache; Jean-Marc (Paris, FR), Costantini; Dominique (Paris, FR), Chaumont; Christine (Paris, FR)
Assignee:	Bioalliance Pharma (Paris, FR)
Filing Date:	Dec 03, 2002
Application Number:	10/307,938
Claims:	1. A prolonged release bioadhesive therapeutic system containing at least one active principle, having an active principle dissolution percentage of more than 70% over 8 hours, comprising quantities of natural proteins representing at least 50% by weight of active principle and at least 20% by weight of said bioadhesive therapeutic system, between 10% and 20% of a hydrophilic polymer, compression excipients, and comprising between 3.5% and 10% of an alkali metal alkylsulphate and between 0.1% and 1% of a monohydrate sugar. 2. A bioadhesive therapeutic system according to claim 1, wherein said bioadhesive therapeutic system is a mucoadhesive tablet. 3. A bioadhesive therapeutic system according to claim 2, wherein the alkali metal alkylsulphate is sodium laurylsulphate or diethylsulphosuccinate. 4. The bioadhesive therapeutic system according to claim 3, in the form of a tablet in which the alkylsulphate is sodium laurylsulphate in a concentration of 3.5% to 10%, of the total weight of the compounds in the tablet. 5. The bioadhesive therapeutic system according to claim 2, in which the sugar monohydrate is lactose monohydrate or saccharose. 6. The bioadhesive therapeutic system according to claim 1, wherein the compression excipients contain corn starch. 7. The bioadhesive therapeutic system according to claim 1, in which one of the active principle is an antifungal from the broad spectrum azole family. 8. The bioadhesive therapeutic system according to claim 7, in the form of a tablet in which the azole is miconazole present in a dose of 10 to 150 mg per tablet. 9. The bioadhesive therapeutic system according to claim 7, in which the active principle is a broad spectrum azole, in association with a further active principle selected from: a polyene type antifungal with a different spectrum; an analgesic; a salivation agent; an antiseptic; a salivary substitute; an anti-inflammatory (corticoids); an antibiotic; thalidomide; or a mixture thereof. 10. The bioadhesive therapeutic system according to claim 9, in which the second active principle is a polyene in a dose of 10 to 100 mg per tablet. 11. The bioadhesive therapeutic system according to claim 9, further comprising 0.1% to 10% by weight of anaesthetic and/or 0.1% to 10% by weight of salivation agent. 12. The bioadhesive therapeutic agent according to claim 1, in which the active principle is an antiseptic. 13. The bioadhesive therapeutic system according to claim 12, in which the antiseptic is sodium laurylsulphate in a minimum concentration of 3.5% by weight. 14. The bioadhesive therapeutic system according to claim 1, in which the active principle is an antiviral that is active for HSV viruses (herpes) VZV (varicella zoster virus), Epstein-Barr virus (infectious mononucleosis, hairy leukoplakia), cytomegalovirus. 15. The bioadhesive therapeutic system according to claim 14, in which the antiviral is present either in an amount of 20 to 100 mg or 10 to 2000 mg. 16. The bioadhesive therapeutic system according to claim 1, in which the active principle is an antiviral active against HIV virus (human immunodeficiency virus). 17. The bioadhesive therapeutic system according to claim 16, in which the active principle is present in an amount of 10 to 2000 mg per bioadhesive therapeutic system. 18. The bioadhesive therapeutic system according to claim 1, in which the active principle is an insoluble analgesic from the opioid family. 19. The bioadhesive therapeutic system according to claim 18, in which the insoluble anagesic from the opioid family is present in an amount of 50 to 1600 micrograms per bioadhesive therapeutic system. 20. The method for preparing a prolonged release mucosal bioadhesive therapeutic system containing at least one active principle, with a dissolution percentage of the active principle that is more than 70% over 8 hours, comprising at least: mixing at least one active principle with natural proteins, these latter representing at least 50% by weight of the active principle, and with excipients and fillers comprising at least one hydrophilic polymer; and further mixing with an alkali metal alkylsulphate in a concentration range 3.5% to 10% by weight of the extended release mucosal bioadhesive therapeutic system. 21. A method preparing a bioadhesive therapeutic system tablet comprising the following steps: a) mixing at least one active principle with natural proteins, these latter representing at least 50% by weight of the active principle, with excipients and fillers comprising at least one hydrophilic polymer; and b) wetting the mixture obtained at a) with a monohydrate sugar or polyol; c) drying the mixture and sizing the grains obtained; and d) further mixing with an alkali metal alkylsulphate in a concentration in the range 3.5% to 10% by weight of the tablet. 22. The method according to claim 21, in which the wetting step b) is followed by a granulation step carried out in the absence of alcohol. 23. The method according to claim 21, in which the sugar monohydrate is lactose monohydrate in a concentration in the range 0.1% to 1%. 24. The method according to claim 21, in which the alkali metal alkylsuiphate is sodium laurylsulphate or sodium diethylsulphosuccinate. 25. The method according to claim 21, in which the active principle or active principles can, if necessary, be associated with a further active principle selected from: a polyane type antifungal with a different spectrum; analgesic' a salivation agent; an antiseptic; a salivary substitute; an antl-inflammitory (corticolds); an antibiotic' thalldomide; or mixtures thereof. 26. A method for treating viral infections which comprises administering to a patient in need thereof a bioadhesive therapeutic system according to claim 14. 27. The method according to claim 26, in which the active principle is an antiviral anti-infectious agent that is active for HSV viruses (herpes), VZV (varicella zoster virus), Epstein-Barr virus (infectious mononucleosis, hairy leukoplakia), cytomegalovirus. 28. The method according to claim 26, in which the active principle is an antiviral anti-infectious agent that is active against HIV virus (human immunodeficiency virus) and is present in an amount of 10 to 2000 mg per bioadhesive therapeutic system. 29. A tablet according to claim 4, in which the sodium lauryisuiphate is in a concentration of 4% to 6% of the total weight of the compounds in the tablet. 30. A bioadhesive therapeutic system according to claim 7, in which the antifungal from the broad spectrum azole family is selected from the group consisting of miconazole, clotrimazole, ketoconazole, fluconazole, itraconazole, isoconazole, econazole, saperconazole, genaconazole, terconazole, butoconazole, tioconazole, oxiconazole, bifonazole, fenticonazole, omoconazole, sertaconazole and sulconazole. 31. The bioadhesive therapeutic system according to claim 8, in which the micoazole is present in a dose of 25 to 75 mg per tablet. 32. The bioadhesive therapeutic system according to claim 8, in which the miconazole is present in a dose of 50 mg per table. 33. The bioadhesive therapeutic system according to claim 10, in which the polyene is in a dose of 20 to 90 mg. 34. The bioadhesive therapeutic system according to claim 14, in which the antiviral is acyclovir, valaciclovir, zidovudine or ganciclovir. 35. The bioadhesive therapeutic according to claim 34, in which the aciclovir and valaciclovir are present in an amount of 50 mg, and the zidovudine and ganciclovir are present in an amount of 500 to 1500 mg. 36. The bioadhesive therapeutic system according to claim 16, in which the antiviral is zidovudine (AZT). 37. The bioadhesive therapeutic system according to claim 17, which is a vaginal system. 38. The bioadhesive therapeutic system according to claim 17, in which the active principle is present in an amount of 500 to 1500 mg. 39. The bioadhesive therapeutic system according to claim 18, in which the insoluble analgesic is fentanyl. 40. The bioadhesive therapeutic system according to claim 39, which the fentanyl is an insoluble base. 41. The bioadhesive therapeutic system according to claim 39, in which the fentanyl is present in an amount of 200 to 1200 micrograms. 42. The method according to claim 20, in which the alkali metal sulphate concentration is in the range of 4% to 6%. 43. The method according to claim according to claim 21, in which the alkali metal sulphate concentration is in the range of 4% to 6%. 44. The method according to claim 27, which the antiviral anti-infectious agent is acyclovir or valaciclovir present in an amount of 20to 100mg per therapeutic system or AZT present in an amount of 10 to 2000 mg per therapeutic system. 45. The method according to claim 44, in which the AZT is present in an amount of 500 to 1500 mg per therapeutic system. 46. The method according to claim 28, in which the antiviral anti-infectious agent is AZT present in an amount of 10 to 2000 mg per therapeutic system. 47. The method according to claim 46, in which the AZT is present in an amount of 500 to 1500 mg per therapeutic system. 48. A method for treating diseases of the mucosa which comprises administering to a patient in need thereof, a bioadhesive therapeutic system according to claim 1, wherein said active principle is miconazole present in a dosage of 25 to 75 mg per tablet.